RJA
CORT icon

Raymond James & Associates’s Corcept Therapeutics CORT Stock Holding History

Raymond James & Associates’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.16M Buy
46,590
+14,640
+46% +$520K ﹤0.01% 2179
2024
Q2 		$1.04M Buy
31,950
+4,401
+16% +$121K ﹤0.01% 2600
2024
Q1 		$694K Buy
+27,549
New +$651K ﹤0.01% 2846
2022
Q4 		– Sell
-33,149
Closed -$850K – 3945
2022
Q3 		$850K Buy
33,149
+951
+3% +$25.4K ﹤0.01% 2510
2022
Q2 		$766K Buy
+32,198
New +$701K ﹤0.01% 2629
2021
Q1 		– Sell
-70,264
Closed -$1.84M – 4012
2020
Q4 		$1.84M Sell
70,264
-8,902
-11% -$188K ﹤0.01% 1934
2020
Q3 		$1.38M Sell
79,166
-8,665
-10% -$138K ﹤0.01% 1984
2020
Q2 		$1.48M Sell
87,831
-23,701
-21% -$333K ﹤0.01% 1908
2020
Q1 		$1.33M Sell
111,532
-86,132
-44% -$1.07M ﹤0.01% 1809
2019
Q4 		$2.39M Buy
197,664
+28,807
+17% +$401K ﹤0.01% 1719
2019
Q3 		$2.39M Sell
168,857
-5,402
-3% -$66.4K ﹤0.01% 1670
2019
Q2 		$1.94M Buy
174,259
+48,478
+39% +$540K ﹤0.01% 1822
2019
Q1 		$1.48M Sell
125,781
-56,739
-31% -$705K ﹤0.01% 1964
2018
Q4 		$2.44M Buy
182,520
+113,543
+165% +$1.5M ﹤0.01% 1527
2018
Q3 		$967K Buy
68,977
+19,307
+39% +$270K ﹤0.01% 2283
2018
Q2 		$781K Buy
49,670
+8,302
+20% +$144K ﹤0.01% 2365
2018
Q1 		$681K Buy
41,368
+1,505
+4% +$27.9K ﹤0.01% 2375
2017
Q4 		$720K Sell
39,863
-54,885
-58% -$994K ﹤0.01% 2315
2017
Q3 		$1.83M Buy
94,748
+6,720
+8% +$100K ﹤0.01% 1707
2017
Q2 		$1.04M Buy
88,028
+42,628
+94% +$463K ﹤0.01% 2002
2017
Q1 		$498K Buy
+45,400
New +$399K ﹤0.01% 2376

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Raymond James & Associates's CORT Position: Q3 2024 in Review

Raymond James & Associates increased its Corcept Therapeutics (CORT) stake by 46% in Q3 2024, buying an estimated $520K and bringing the position to 46,590 shares worth $2.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2179.

Raymond James & Associates first reported a position in CORT in Q1 2017 and has held it in 21 quarters since. The position peaked at $2.44M in Q4 2018. 321 funds tracked by Wall St. Rank hold CORT as of Q3 2024.

  • Raymond James & Associates held 46,590 shares of Corcept Therapeutics worth $2.16M as of Q3 2024.
  • Raymond James & Associates bought 14,640 Corcept Therapeutics shares in Q3 2024, an estimated $520K.
  • Corcept Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2179 holding.
  • Raymond James & Associates first reported a position in Corcept Therapeutics in Q1 2017 and has held it in 21 quarters since.
  • Raymond James & Associates's Corcept Therapeutics position peaked at $2.44M in Q4 2018.
  • 321 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.